Microbiome Characteristics and short-chain FATty acid metabolism in type 1 diabetes patients versus healthy controls - MCFAT

Academisch Medisch Centrum0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Definite diagnosis of type 1 diabetes i.e. positive auto-antibodies or unambiguous clinical picture
•2. no concomitant medication (no statins, ACE/ATII inhibitors, PPI nor antibiotics)
•3. Normal BMI: 18-25 kg/m2
•4. A balanced, *western* diet (see appendix);healthy controls:
•1. normal BMI
•2. Caucasian
•3. Balanced, 'western' diet

•1. Ambiguous clinical picture i.e. features of type 2, or other types of diabetes
•2. Complications of diabetes (retinopathy/neuropathy/microalbuminuria)
•3. Medication use (eg statins, ACE/ATII inhibitors, PPI).
•4. Antibiotic use in the last three months
•5. (Regular) use of probiotics-containing food
•6. A diet that is one-sided or unusual (see appendix)
•7. Medical conditions that can be expected to affect glucose metabolism or gut microbiome
•8. Chronic diarrhea;Healthy controls:
•1. Medication use
•2. Comorbid conditions
•3. Antibiotic use in the last three months
•4. (regular) use of probiotics-containing food
•5. A one sided or unusual diet
•6. Diarrhea

发起方